For the Inventor, By the Inventor

Enter assignee name

Tuebingen, Germany

Immatics Biotechnologies Gmbh

USPTO Granted Patents = 725

CIPO Patents = 24

EPO Patents = 95

Trademarks = 23

Forward Citations = 5,487

Loading Chart...

Loading Chart...

104 inventors (with patents filed for the assignee):

Toni Weinschenk (603 out of 606 patents)

Jens Fritsche (563 out of 567 patents)

Oliver Schoor (536 out of 539 patents)

4. Harpreet Singh (502 out of 505 patents)

5. Andrea Mahr (347 out of 348 patents)

6. Colette Song (212 out of 213 patents)

7. Daniel Johannes Kowalewski (158 out of 159 patents)

8. Heiko Schuster (150 out of 152 patents)

9. Franziska Hoffgaard (75 out of 76 patents)

10. Steffen Walter (75 out of 79 patents)

11. Chih-Chiang Tsou (74 out of 74 patents)

12. Anita Wiebe (74 out of 74 patents)

13. Hans-Georg Rammensee (67 out of 68 patents)

14. Lea Stevermann (57 out of 57 patents)

15. Claudia Wagner (48 out of 49 patents)

Core Competencies:

Immunotherapy

Peptides

Cancer Treatments

T Cell Receptors

HLA Displayed Peptides

MAGEB2 Binding Constructs

Antigen Binding Proteins

Peptide-MHC Affinity Screening

Head and Neck Squamous Cell Carcinoma

Pancreatic Cancer

Lung Cancer

Renal Cell Carcinoma

725 patents: Sort by Forward Citations

1. 12351616 - Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers (2025-07-08),

2. 12318407 - Peptides displayed by HLA for use in immunotherapy against different types of cancers (2025-06-03),

3. 12312412 - MAGEB2 binding constructs (2025-05-27),

4. 12297254 - Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers (2025-05-13),

5. 12297252 - T cell receptors with improved pairing (2025-05-13),

6. 12297245 - Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers (2025-05-13),

7. 12295996 - Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers (2025-05-13),

8. 12295995 - Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers (2025-05-13),

9. 12295994 - Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers (2025-05-13),

10. 12290530 - Peptides displayed by HLA for use in immunotherapy against different types of cancers (2025-05-06),

11. 12285443 - Peptides displayed by HLA for use immunotherapy against different types of cancers (2025-04-29),

12. 12281146 - Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers (2025-04-21),

13. 12275776 - Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers (2025-04-14),

14. 12275775 - Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers (2025-04-14),

15. 12275768 - In immunotherapy against lung cancer, including NSCLC, SCLC and other cancers (2025-04-14),

IMMATICS Biotechnologies GmbH is a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapies. With its headquarters in Germany, IMMATICS leverages its proprietary XmAb cell therapy platform to discover, develop, and manufacture cutting-edge immunotherapies with the potential to transform cancer treatment. The company's vision is to harness the power of the immune system to significantly improve outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

725 Patents

#1 in Tuebingen

#71 in Germany

#1,342 in the World

Tuebingen, Germany

Immatics Biotechnologies Gmbh

Forward Citations = 5,487

104 inventors:

Toni Weinschenk (603 out of 606 patents)

Jens Fritsche (563 out of 567 patents)

Oliver Schoor (536 out of 539 patents)

4. Harpreet Singh (502 out of 505 patents)

5. Andrea Mahr (347 out of 348 patents)

Please report any incorrect information to support@idiyas.com

Loading…